This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

ELIQUIS® Dosing & Switching

ELIQUIS Dosing for your patients with NVAF

ELIQUIS Dosing for your patients with DVT / PE

ELIQUIS dosing for your patients with renal and/or hepatic impairment

Switching from and to ELIQUIS

Quick Reference Dosing Guide

Footnotes:

  • DVT = Deep Vein Thrombosis   NVAF = Non-Valvular Atrial Fibrillation   PE= Pulmonary Embolism

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie

Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com